Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
6.87 (1y: -1%)
Market Cap 296.7 M P/E(ttm) 83.90
Enterprise Value 305.36 M P/B 6.70
SCMP- NAS (USA)
Sucampo Pharmaceuticals, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$6.87
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry		 vs
history
Cash to Debt 1.099
SCMP's Cash to Debt is ranked higher than
59% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. SCMP: 1.099 )
SCMP' s 10-Year Cash to Debt Range
Min: 1.1   Max: No Debt
Current: 1.1
Equity to Asset 0.337
SCMP's Equity to Asset is ranked lower than
53% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. SCMP: 0.337 )
SCMP' s 10-Year Equity to Asset Range
Min: -0.51   Max: 0.86
Current: 0.34
-0.51
0.86
Interest Coverage 3.8
SCMP's Interest Coverage is ranked higher than
62% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.70 vs. SCMP: 3.8 )
SCMP' s 10-Year Interest Coverage Range
Min: 4   Max: No Debt
Current: 3.8
F-Score: 6
Z-Score: 2.73
M-Score: -3.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry		 vs
history
Operating margin (%) 10.20
SCMP's Operating margin (%) is ranked higher than
74% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.80 vs. SCMP: 10.20 )
SCMP' s 10-Year Operating margin (%) Range
Min: -904   Max: 28
Current: 10.2
-904
28
Net-margin (%) 5.9
SCMP's Net-margin (%) is ranked higher than
67% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. SCMP: 5.9 )
SCMP' s 10-Year Net-margin (%) Range
Min: -906.5   Max: 41.4
Current: 5.9
-906.5
41.4
ROE (%) 11.2
SCMP's ROE (%) is ranked higher than
83% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. SCMP: 11.2 )
SCMP' s 10-Year ROE (%) Range
Min: -374.7   Max: 56.6
Current: 11.2
-374.7
56.6
ROA (%) 3.8
SCMP's ROA (%) is ranked higher than
70% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.40 vs. SCMP: 3.8 )
SCMP' s 10-Year ROA (%) Range
Min: -109.7   Max: 32.5
Current: 3.8
-109.7
32.5
ROC (Joel Greenblatt) (%) 53.80
SCMP's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.40 vs. SCMP: 53.80 )
SCMP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -119.6   Max: 194.4
Current: 53.8
-119.6
194.4
Revenue Growth (%) 4.9
SCMP's Revenue Growth (%) is ranked higher than
76% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. SCMP: 4.9 )
SCMP' s 10-Year Revenue Growth (%) Range
Min: -16.3   Max: 85.2
Current: 4.9
-16.3
85.2
EBITDA Growth (%) 34.6
SCMP's EBITDA Growth (%) is ranked higher than
99% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. SCMP: 34.6 )
SCMP' s 10-Year EBITDA Growth (%) Range
Min: -58.9   Max: 34.6
Current: 34.6
-58.9
34.6
ยป SCMP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

SCMP Guru Trades in Q2 2012

Jim Simons 142,700 sh (+139.83%)
» More
Q3 2012

SCMP Guru Trades in Q3 2012

Jim Simons 141,600 sh (-0.77%)
» More
Q4 2012

SCMP Guru Trades in Q4 2012

Jim Simons 185,500 sh (+31%)
» More
Q1 2013

SCMP Guru Trades in Q1 2013

Steven Cohen 21,583 sh (New)
Jim Simons 208,200 sh (+12.24%)
» More
» Details

Insider Trades

Latest Guru Trades with SCMP



No Insider Trades Found!
ยป Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/E(ttm) 83.90
SCMP's P/E(ttm) is ranked lower than
61% of the 497 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.30 vs. SCMP: 83.90 )
SCMP' s 10-Year P/E(ttm) Range
Min: 5.52   Max: 411
Current: 83.9
5.52
411
P/B 6.70
SCMP's P/B is ranked lower than
62% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.46 vs. SCMP: 6.70 )
SCMP' s 10-Year P/B Range
Min: 1.18   Max: 9.89
Current: 6.7
1.18
9.89
P/S 3.40
SCMP's P/S is ranked higher than
57% of the 654 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.68 vs. SCMP: 3.40 )
SCMP' s 10-Year P/S Range
Min: 1.2   Max: 7.19
Current: 3.4
1.2
7.19
PFCF 229.10
SCMP's PFCF is ranked lower than
58% of the 399 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.96 vs. SCMP: 229.10 )
SCMP' s 10-Year PFCF Range
Min: 3.68   Max: 346.4
Current: 229.1
3.68
346.4
EV-to-EBIT 52.6
SCMP's EV-to-EBIT is ranked lower than
56% of the 496 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.43 vs. SCMP: 52.6 )
SCMP' s 10-Year EV-to-EBIT Range
Min: 0.9   Max: 66.7
Current: 52.6
0.9
66.7
Shiller P/E 78.8
SCMP's Shiller P/E is ranked lower than
100% of the Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: vs. SCMP: 78.8 )
SCMP' s 10-Year Shiller P/E Range
Min: 46.4   Max: 105.44
Current: 78.8
46.4
105.44

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 24.5
SCMP's Price/Net Current Asset Value is ranked higher than
52% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.20 vs. SCMP: 24.5 )
SCMP' s 10-Year Price/Net Current Asset Value Range
Min: 15.3   Max: 50.6
Current: 24.5
15.3
50.6
Price/Tangible Book 8.1
SCMP's Price/Tangible Book is ranked lower than
63% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. SCMP: 8.1 )
SCMP' s 10-Year Price/Tangible Book Range
Min: 1.5   Max: 8.7
Current: 8.1
1.5
8.7
Price/DCF (Projected) 4.7
SCMP's Price/DCF (Projected) is ranked higher than
51% of the 283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. SCMP: 4.7 )
SCMP' s 10-Year Price/DCF (Projected) Range
Min: 1.4   Max: 6.7
Current: 4.7
1.4
6.7
Price/Median PS Value 1.1
SCMP's Price/Median PS Value is ranked higher than
59% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. SCMP: 1.1 )
SCMP' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 2.7
Current: 1.1
0.7
2.7
Price/Graham Number 4.6
SCMP's Price/Graham Number is ranked lower than
62% of the 422 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.00 vs. SCMP: 4.6 )
SCMP' s 10-Year Price/Graham Number Range
Min: 1   Max: 4.7
Current: 4.6
1
4.7
Earnings Yield (Greenblatt) 1.90
SCMP's Earnings Yield (Greenblatt) is ranked higher than
59% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. SCMP: 1.90 )
SCMP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.5   Max: 108.7
Current: 1.9
1.5
108.7
Forward Rate of Return (Yacktman) 1.19
SCMP's Forward Rate of Return (Yacktman) is ranked higher than
81% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. SCMP: 1.19 )
SCMP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1   Max: 2
Current: 1.19
1
2

Business Description

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones for the treatment of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders for which there are unmet or underserved medical needs and commercial potential. The therapeutic potential of prostones was first identified by one of the company's founders. Two prostone-based products have received marketing approval: Amitiza for the treatment of chronic idiopathic constipation in adults and irritable bowel syndrome with constipation in adult women and Rescula for the treatment of glaucoma. Sucampo is mainly responsible for Amitiza research and development efforts and are the holder of the new drug application. Takeda is mainly responsible for the marketing and commercialization of Amitiza in the United States and Canada and markets Amitiza to office-based specialty physicians and primary care physicians in the United States and funds a portion of the research and development activities. Sucampo is currently pursuing marketing approval for Amitiza for opioid-induced bowel dysfunction in patients with non-malignant pain, a constipation-related gastrointestinal indication. Opioid pain relievers are prescribed for patients with chronic and acute pain, many of whom also develop opioid-induced bowel dysfunction. Sucampo is developing other prostone-based compounds for the treatment of a range of diseases. The most advanced of these programs are: Cobiprostone is currently in a phase 2 clinical trial for the prevention of ulcers induced by non-steroidal anti-inflammatory drugs. SPI-017 is being researched as a treatment of peripheral arterial and vascular disease and central nervous system disorders. Sucampo is developing the prostone compound cobiprostone for oral administration to treat various gastrointestinal and liver disorders, including NSAID-induced ulcers and portal hypertension. The company also plans to develop an inhaled formulation of cobiprostone for the treatment of respiratory symptoms of cystic fibrosis and chronic obstructive pulmonary disease. The company holds worldwide royalty-bearing license to develop and commercialize Amitiza and other prostone-based compounds covered by patents and patent applications from Sucampo AG, an affiliated Swiss patent-holding company.
Company Website
SEC Reports
Industry: Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX
Traded in other countries:R3A.Germany
ยป More Articles for SCMP

Headlines

Articles On GuruFocus.com
comment on SCMP Mar 06 2013 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 08 2011 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 03 2010 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) May 10 2010 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 06 2009 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 07 2009 
Sucampo Pharmaceuticals Reports Financial Results for the Second Quarter of 2009 Aug 06 2009 
Sucampo to Release Second Quarter 2009 Financial Results and Conduct a Conference Call on August 6, Jul 31 2009 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) May 11 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK